Latest news
Vanda Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 07:03:59 GMTVNDA: Fanapt and NEREUS drive growth as BYSANTI approval and pipeline advances set stage for expansion - TradingViewTradingView · Wed, 05 Aug 2026 21:47:32 GMTVNDA: Q2 2026 saw revenue fall 4% and a net loss of $62.5M, with HETLIOZ® sales down 66% and Fanapt® up 23% - TradingViewTradingView · Wed, 05 Aug 2026 11:40:20 GMT